Age's Impact on Liraglutide Pharmacokinetics Explored in Healthy Volunteers

Liraglutide, a GLP-1 receptor agonist, is a widely used medication for managing type 2 diabetes and obesity. Its efficacy and safety depend on how the body processes the drug, a field known as pharmacokinetics. As individuals age, physiological changes can significantly alter drug absorption, distribution, metabolism, and excretion. This Phase 1 study aimed to understand if and how age influences the pharmacokinetic profile of Liraglutide in healthy individuals.

This Phase 1 trial aimed to comprehensively compare the pharmacokinetic profile of Liraglutide between young and elderly healthy individuals. While specific quantitative results were not detailed in the provided abstract, the study's primary objective was to assess the Area Under the Curve (AUC 0-t), a critical measure of overall drug exposure over time. Secondary endpoints included the maximum plasma concentration (Cmax), the time to reach Cmax (tmax), and the terminal plasma elimination half-life (t½), all crucial for understanding drug disposition. The researchers also monitored for adverse events to evaluate safety across age groups. The core objective of this study was to quantitatively compare Liraglutide's systemic exposure and elimination kinetics between young and elderly healthy volunteers, providing foundational data for potential age-related dosing adjustments.